JK
John K. Bell
Lead Independent Director, Chair of Audit Committee
Edison OncologyEdison Oncology Pipeline
| Drug | Indication | Phase |
|---|
| Orotecan™ | Oncology (unspecified) | Phase 1/2a |
| EO1001 | ErbB-Driven Tumors | Phase not specified (Clinical/Preclinical) |
| EO-4426 | CDA-High Cancers | Phase not specified (Clinical/Preclinical) |